Purebread Brands (BRED.V): The best thing since sliced bread got crap
Voyageur Pharmaceuticals (VM) took a mine and turned it into a pharma company
Can your phone confirm you have strep throat? Light AI (ALGO.E) says yes
Prospera Energy (PEI.V)’s big corporate evolution: From incompetence to dishonesty
Brera Holdings (BREA.Q) pioneering pubco sports investment model, but is it a win?
“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes. Read full article: https://equity.guru/2021/06/21/core-one-cool-c-subsidiary-begins-development-of-psychedelic-drug-formulation-for-stroke-treatment/
